We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
BAVENCIO (Merck Serono Australia Pty Ltd)
Product name
BAVENCIO
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
218 working days (255)
Active ingredients
avelumab (rch)
Registration type
NCE/NBE
Indication
BAVENCIO is indicated for the treatment of adults and paediatric patients 12 years and older with metastatic Merkel Cell Carcinoma (mMCC).
Registration process
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.